These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34180043)

  • 1. 1st Post-European Headache Federation Meeting: a review of the latest developments presented at the 2020 European Headache Federation Congress.
    Láinez-Andrés JM; Ashina M; Belvís R; Díaz-Insa S; Ezpeleta D; García-Azorín D; González-Oria C; Guerrero AL; Guillém A; Holle-Lee D; Huerta-Villanueva M; Irimia P; Leira R; Pascual J; Porta-Etessam J; Pozo-Rosich P; Rodríguez-Vico JS; Sánchez Del Río M; Santos-Lasaosa S; Silberstein S
    Rev Neurol; 2021 Jun; 72(s02):S1-S19. PubMed ID: 34180043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Migraine--the forgotten epidemic: development of the EHF/WHA Rome Declaration on Migraine.
    Diener HC; Steiner TJ; Tepper SJ
    J Headache Pain; 2006 Dec; 7(6):433-7. PubMed ID: 17149560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine.
    Friedman DI; Cohen JM
    Emerg Top Life Sci; 2020 Sep; 4(2):179-190. PubMed ID: 32832978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment.
    Silberstein SD; Rapoport AM; Loupe PS; Aycardi E; McDonald M; Yang R; Bigal ME
    Headache; 2019 Mar; 59(3):383-393. PubMed ID: 30450545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world preventative drug management of migraine among Spanish neurologists.
    García-Azorin D; Santos-Lasaosa S; Gago-Veiga AB; Viguera Romero J; Guerrero-Peral AL
    J Headache Pain; 2019 Feb; 20(1):19. PubMed ID: 30770719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials.
    Halker Singh RB; Aycardi E; Bigal ME; Loupe PS; McDonald M; Dodick DW
    Cephalalgia; 2019 Jan; 39(1):52-60. PubMed ID: 29722276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():276-290. PubMed ID: 30403405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.
    Sacco S; Lampl C; Maassen van den Brink A; Caponnetto V; Braschinsky M; Ducros A; Little P; Pozo-Rosich P; Reuter U; Ruiz de la Torre E; Sanchez Del Rio M; Sinclair AJ; Martelletti P; Katsarava Z;
    J Headache Pain; 2021 May; 22(1):39. PubMed ID: 34006218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fremanezumab for the prevention of chronic and episodic migraine.
    Lionetto L; Cipolla F; Guglielmetti M; Martelletti P
    Drugs Today (Barc); 2019 Apr; 55(4):265-276. PubMed ID: 31050694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Winner PK; Spierings ELH; Yeung PP; Aycardi E; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y
    Headache; 2019 Nov; 59(10):1743-1752. PubMed ID: 31675102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fremanezumab for the preventive treatment of migraine in adults.
    Lionetto L; Curto M; Cisale GY; Capi M; Cipolla F; Guglielmetti M; Martelletti P
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):741-748. PubMed ID: 31220963
    [No Abstract]   [Full Text] [Related]  

  • 13. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation.
    Vatzaki E; Straus S; Dogne JM; Garcia Burgos J; Girard T; Martelletti P
    J Headache Pain; 2018 Aug; 19(1):68. PubMed ID: 30109437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines.
    Cohen JM; Dodick DW; Yang R; Newman LC; Li T; Aycardi E; Bigal ME
    Headache; 2017 Oct; 57(9):1375-1384. PubMed ID: 28862758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CGRP pathway monoclonal antibodies for cluster headache.
    Chan C; Goadsby PJ
    Expert Opin Biol Ther; 2020 Aug; 20(8):947-953. PubMed ID: 32241175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.
    Silberstein SD; McAllister P; Ning X; Faulhaber N; Lang N; Yeung P; Schiemann J; Aycardi E; Cohen JM; Janka L; Yang R
    Headache; 2019 Jun; 59(6):880-890. PubMed ID: 30977520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
    Silberstein SD; Cohen JM; Yang R; Gandhi SK; Du E; Jann AE; Marmura MJ
    J Headache Pain; 2021 Jan; 22(1):2. PubMed ID: 33413075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH).
    Sacco S; Merki-Feld GS; Ægidius KL; Bitzer J; Canonico M; Gantenbein AR; Kurth T; Lampl C; Lidegaard Ø; Anne MacGregor E; MaassenVanDenBrink A; Mitsikostas DD; Nappi RE; Ntaios G; Paemeleire K; Sandset PM; Terwindt GM; Vetvik KG; Martelletti P;
    J Headache Pain; 2018 Aug; 19(1):76. PubMed ID: 30171365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.
    Ossipov MH; Raffa RB; Pergolizzi JV
    Drugs Today (Barc); 2020 Jan; 56(1):5-19. PubMed ID: 32055802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fremanezumab for the Preventive Treatment of Chronic Migraine.
    Silberstein SD; Dodick DW; Bigal ME; Yeung PP; Goadsby PJ; Blankenbiller T; Grozinski-Wolff M; Yang R; Ma Y; Aycardi E
    N Engl J Med; 2017 Nov; 377(22):2113-2122. PubMed ID: 29171818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.